Total Payments
$1,049
2024 Payments
$406.19
Companies
14
Transactions
37
Medicare Patients
2,064
Medicare Billing
$506,901
Payment Breakdown by Category
Food & Beverage$1,049 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,049 | 37 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $200.56 | 6 | $0 (2022) |
| ABBVIE INC. | $184.81 | 5 | $0 (2023) |
| Lilly USA, LLC | $137.32 | 2 | $0 (2024) |
| Axsome Therapeutics, Inc. | $121.34 | 1 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $72.90 | 4 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.48 | 4 | $0 (2021) |
| Collegium Pharmaceutical, Inc. | $62.76 | 3 | $0 (2021) |
| Averitas Pharma Inc. | $53.81 | 3 | $0 (2024) |
| Abbott Laboratories | $39.18 | 2 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $33.38 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $406.19 | 11 | Axsome Therapeutics, Inc. ($121.34) |
| 2023 | $153.59 | 4 | ABBVIE INC. ($135.53) |
| 2022 | $249.84 | 8 | Neurocrine Biosciences, Inc. ($200.56) |
| 2021 | $239.63 | 14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($68.48) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Neuromodulation | ||||||
| 11/18/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: ANTIBIOTIC | ||||||
| 10/08/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: ANTIBIOTIC | ||||||
| 08/22/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $121.34 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/04/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: ANTIBIOTIC | ||||||
| 04/15/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/03/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Neuromodulation | ||||||
| 03/14/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/22/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $120.12 | General |
| Category: Obesity | ||||||
| 02/21/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: ANTIBIOTIC | ||||||
| 11/02/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: PAIN MANAGEMENT | ||||||
| 05/11/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $118.15 | General |
| Category: NEUROSCIENCE | ||||||
| 03/29/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.93 | General |
| Category: NEUROSCIENCE | ||||||
| 10/12/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Neuropsychiatry | ||||||
| 08/24/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | Cash or cash equivalent | $120.02 | General |
| Category: Neuropsychiatry | ||||||
| 08/18/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Neuropsychiatry | ||||||
| 07/15/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: NEUROSCIENCE | ||||||
| 07/08/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Neuropsychiatry | ||||||
| 06/17/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Neuropsychiatry | ||||||
| 05/31/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Neuropsychiatry | ||||||
| 08/05/2021 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Neuroscience | ||||||
| 05/24/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 436 | 570 | $194,657 | $35,520 |
| 2022 | 4 | 146 | 382 | $166,204 | $19,974 |
| 2021 | 7 | 538 | 1,144 | $203,003 | $91,779 |
| 2020 | 9 | 944 | 4,800 | $812,888 | $359,627 |
Total Patients
2,064
Total Services
6,896
Medicare Billing
$506,901
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 57 | 163 | $64,348 | $7,645 | 11.9% |
| 99493 | Follow-up psychiatric collaborative care management, subsequent calendar month, first 60 minutes | Office | 2023 | 72 | 85 | $30,695 | $7,545 | 24.6% |
| 99492 | Initial psychiatric collaborative care management, first calendar month, first 70 minutes | Office | 2023 | 74 | 75 | $28,125 | $6,979 | 24.8% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 60 | 60 | $46,966 | $5,818 | 12.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 57 | 57 | $6,172 | $2,565 | 41.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 33 | $4,272 | $1,843 | 43.2% |
| 99494 | Psychiatric collaborative care management per calendar month, each additional 30 minutes | Office | 2023 | 34 | 35 | $7,000 | $1,260 | 18.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 27 | 33 | $2,643 | $1,139 | 43.1% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 28 | 29 | $4,437 | $725.29 | 16.3% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 60 | 295 | $116,457 | $12,764 | 11.0% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Office | 2022 | 56 | 56 | $42,211 | $4,518 | 10.7% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 18 | 19 | $5,700 | $2,358 | 41.4% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Office | 2022 | 12 | 12 | $1,836 | $333.60 | 18.2% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 103 | 246 | $95,940 | $58,282 | 60.7% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 104 | 250 | $49,500 | $14,732 | 29.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 106 | 261 | $28,710 | $11,534 | 40.2% |
| 96136 | Psychological or neuropsychological test administration and scoring by qualified health care professional, first 30 minutes | Office | 2021 | 90 | 170 | $13,600 | $3,592 | 26.4% |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | Office | 2021 | 90 | 171 | $10,602 | $2,814 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 13 | $2,176 | $717.18 | 33.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 33 | 33 | $2,475 | $107.46 | 4.3% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 157 | 938 | $365,820 | $219,178 | 59.9% |
| 80307 | Testing for presence of drug | Office | 2020 | 160 | 947 | $187,506 | $54,425 | 29.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 162 | 1,295 | $142,453 | $52,766 | 37.0% |
| 96136 | Psychological or neuropsychological test administration and scoring by qualified health care professional, first 30 minutes | Office | 2020 | 146 | 642 | $51,360 | $16,238 | 31.6% |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | Office | 2020 | 147 | 642 | $39,804 | $12,631 | 31.7% |
About Pamela Gray, NP
Pamela Gray, NP is a Gerontology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/05/2014. The National Provider Identifier (NPI) number assigned to this provider is 1134527237.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Pamela Gray, NP has received a total of $1,049 in payments from pharmaceutical and medical device companies, with $406.19 received in 2024. These payments were reported across 37 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($1,049).
As a Medicare-enrolled provider, Gray has provided services to 2,064 Medicare beneficiaries, totaling 6,896 services with total Medicare billing of $506,901. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gerontology
- Other Specialties Adult Health
- Location Nashville, TN
- Active Since 12/05/2014
- Last Updated 06/24/2025
- Taxonomy Code 363LG0600X
- Entity Type Individual
- NPI Number 1134527237
Products in Payments
- INGREZZA (Drug) $200.56
- VRAYLAR (Drug) $184.81
- Auvelity (Drug) $121.34
- ZEPBOUND (Drug) $120.12
- NUZYRA (Drug) $72.90
- RELISTOR (Drug) $68.48
- XTAMPZA (Drug) $62.76
- QUTENZA (Drug) $53.81
- PROCLAIM (Device) $39.18
- NURTEC ODT (Drug) $33.38
- BELBUCA (Drug) $25.42
- REYVOW (Drug) $18.00
- EMGALITY (Drug) $17.20
- KRYSTEXXA (Biological) $16.90
- Movantik (Drug) $14.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gerontology Doctors in Nashville
Leeann Dennery, Np, NP
Gerontology — Payments: $8,148
Gerontology $8,148
Andrea Davis, Ag-Acnp, AG-ACNP
Gerontology — Payments: $2,910
Gerontology $2,910
Rachel Claiborne, Agnp-C, AGNP-C
Gerontology — Payments: $2,582
Gerontology $2,582
Mrs. Kathleen Ballard, Aprn, APRN
Gerontology — Payments: $2,458
Gerontology $2,458
Kaitlyn Chapin, Msn, Agnp-C, MSN, AGNP-C
Gerontology — Payments: $2,410
Gerontology $2,410
Kimin Huang
Gerontology — Payments: $2,159
Gerontology $2,159